Lannett launches generic Mexitil
Lannett is introducing mexiletine hydrochloride capsules in dosage strengths of 150 mg, 200 mg and 250 mg.
The product is the generic of Boehringer Ingelheim’s Mexitil capsules.
"We have expanded our collaboration with Rivopharm SA to now include all three currently available dosage strengths of Mexiletine," said Tim Crew, Lannett CEO. "For at least the next six months, we believe we will be one of only three suppliers of this medication in the United States. While the market opportunity for this product is relatively modest, patient use has increased meaningfully over the last few years."
Mexiletine hydrochloride capsules had a market value of about $16 million for the 12 months ended May 2020, according to IQVIA, although actual generic market values are expected to be lower.
Under the agreement, Lannett will primarily provide sales, marketing and distribution support for the product, for which it will receive a percentage of net profits. Other financial terms were not disclosed.